TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04875273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Tape® aplicación
Description: Magnetic tape® is applied without creating any tension on the paravertebral skin of the lumbar spine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Tape® aplicación
Description: Magnetic tape® is applied without creating any tension on the paravertebral skin of the lumbar spine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Tape® aplicación
Description: Magnetic tape® is applied without creating any tension on the paravertebral skin of the lumbar spine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Tape® aplicación
Description: Magnetic tape® is applied without creating any tension on the paravertebral skin of the lumbar spine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Tape® aplicación
Description: Magnetic tape® is applied without creating any tension on the paravertebral skin of the lumbar spine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Tape® aplicación
Description: Magnetic tape® is applied without creating any tension on the paravertebral skin of the lumbar spine

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiology Tape application
Description: Kinesiology tape is applied without creating any tension on the paravertebral skin of the lumbar spine

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiology Tape application
Description: Kinesiology tape is applied without creating any tension on the paravertebral skin of the lumbar spine

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiology Tape application
Description: Kinesiology tape is applied without creating any tension on the paravertebral skin of the lumbar spine

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiology Tape application
Description: Kinesiology tape is applied without creating any tension on the paravertebral skin of the lumbar spine

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiology Tape application
Description: Kinesiology tape is applied without creating any tension on the paravertebral skin of the lumbar spine

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiology Tape application
Description: Kinesiology tape is applied without creating any tension on the paravertebral skin of the lumbar spine
Study: NCT05816317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single-Session Mechanism-Focused Intervention (SSMFI)
Description: A brief intervention for patients hospitalized for suicide risk that directly targets hopelessness and perceptions of social relatedness.
Study: NCT05808088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnotherapeutic sound-files
Description: The participants have access to hypnotherapeutic sound files which they can use as the please.
Study: NCT05816317

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Distress Tolerance Skills Review
Description: Treatment as usual at the inpatient setting for this study.
Study: NCT05808088

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypnotherapeutic sound-files
Description: The participants have access to hypnotherapeutic sound files which they can use as the please.
Study: NCT06487494

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circumcision wound closure using 2-octyl cyanoacrylate glue with four interrupted sutures
Description: 2-octyl cyanoacrylate glue is a wound closure adhesive which will be used with four interrupted sutures following circumcision for wound closure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumcision wound closure using continuous sutuing
Description: Continuous suturing is the standard following circumcision for wound closure.
Study: NCT05497505

Intervention type: DEVICE
Intervention: Pacmed Critical
Description: For patients in the On-period, Pacmed Critical will be available as decision support after initial eligibility screening for ICU discharge by treatment team
Study: NCT05068596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: expermintal
Description: progressive resistive functional strength training in the plantigrade foot position plus designed physical therapy program

Intervention type: OTHER
Group type: OTHER
Intervention: CONTROL
Description: Designed physical therapy program
Study: NCT05777811

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertically coronally advanced flap combined with connective tissue graft.
Description: The exposed root surfaces are planed with Gracey 1-2 curettes. An intrasulcular incision is made with a blade on the buccal aspects of the involved teeth. The incision is extended horizontally to the adjacent papilla. Then, slightly divergent vertical releasing incisions are carried 2 mm beyond the mucogingival junction. A full-thickness flap is raised with a periosteal elevator towards the mucogingival junction. After that, a partial-thickness dissection is carried out in the apical direction to release muscle tension and provide coronal advancement of the flap. The adjacent papillae are de-epithelialized. The connective tissue graft (CTG) is harvested from the lateral palate using the de-epithelialized gingival graft technique. After harvesting, the connective tissue graft is sutured to the recipient bed. Finally, the flap is positioned 2 mm over the cementoenamel junction and sutured with 6-0 polypropylene sutures. No periodontal dressing is applied.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft
Description: A partial-thickness flap is elevated (using a blade #15c) with horizontal incisions at the cemento-enamel junction (CEJ) level of the adjacent teeth. Then, two vertical incisions extending to the apical are made from the two ends of the horizontal incision. The epithelium in the framed region is removed with a scalpel, and the underlying connective tissue is exposed. To achieve the best vascularization of the free gingival graft from the recipient site, bed preparation is completed with a split-thickness horizontal incision that joins the vertical incisions in the apical region. The free gingival graft is stabilized using interrupted sutures and a sling suture.
Study: NCT05863364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose of Rifaximin
Description: The patients in group B were given rifaximin with the dose of 600mg/d (600mg, qd) for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional dose of Rifaximin
Description: the patients in group C were delivered 1200mg/d (600mg, bid) for 24 weeks
Study: NCT05615350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meals served during breakfast with a wide range of different food textures
Description: Ad libitum portions of twelve different meals with a wide range of food textures served during breakfast at the eating behaviour lab

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meals served during lunch with a wide range of different food textures
Description: Ad libitum portions of twelve different meals with a wide range of food textures served during lunch at the eating behaviour lab
Study: NCT06356597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab with Fruquintinib, Metronidazole
Description: Metronidazole tablets: One administration cycle is every 6 weeks, and metronidazole tablets are given orally on the 1st to 7th day of each cycle. The medication method is two tablets three times one day.~Teralizumab: Every 3 weeks is a dosing cycle, with 200mg of Teralizumab administered intravenously on the first day of each cycle.
Study: NCT05783323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib monotherapy
Description: Patients will receive larotrectinib monotherapy for 6 months at the FDA-approved dose.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 131I therapy
Description: Patients will receive 131I therapy after 6 months of larotrectinib.
Study: NCT06359535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542
Description: This study is an economic study and does not interfere with patients' medical treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542
Description: This study is an economic study and does not interfere with patients' medical treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542
Description: This study is an economic study and does not interfere with patients' medical treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05206604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07295324
Description: Ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07259955
Description: Cream
Study: NCT06116032

Intervention type: DIAGNOSTIC_TEST
Intervention: Methylation Cytometry
Description: Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.

Intervention type: DIAGNOSTIC_TEST
Intervention: Methylation Cytometry
Description: Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.

Intervention type: DIAGNOSTIC_TEST
Intervention: Methylation Cytometry
Description: Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.
Study: NCT04509011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluobeam® LX
Description: Fluobeam®-LX is used to identify and evaluate parathyroid glands using auto-fluorescence during thyroid surgery.
Study: NCT06270394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-Fibroblast activation protein inhibitor
Description: Fibroblast activation protein (FAP), a type II transmembrane serine protease with dipeptidyl peptidase and endopeptidase activities. FAP is a specific surface marker for activated fibroblasts in the mesenchyme of tumors, which account for 90% of the stroma of epithelial neoplasms. FAP inhibitors (FAPIs) can specifically target and bind to FAP. These inhibitors that are radiolabeled with gallium 68 (68Ga-FAPIs) can be probes for visualization of the FAP tumor stroma. Previous studies have demonstrated that 68Ga-FAPI-04 is not dependent on blood glucose levels, has an equal or better tumor-to-background ratio, and clearly visualizes primary tumors and their metastatic foci. In addition, previous studies on 68Ga-FAPI-04 have focused on PET/CT and the efficacy of PET/MR with FAPI for postoperative evaluation of GI tumors remains to be clarified.
Study: NCT04307355

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcu O2®
Description: Participants randomized into study active group will be provided with a Transcu O2® at their surgical site and followed for 4 weeks.
Study: NCT05410795

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: Enrolled subjects will be examined with MRI of pancreas, and the volume, length and thickness of coronal plane of pancreas will be measured by software.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: Enrolled subjects will be examined with MRI of pancreas, and the volume, length and thickness of coronal plane of pancreas will be measured by software.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: Enrolled subjects will be examined with MRI of pancreas, and the volume, length and thickness of coronal plane of pancreas will be measured by software.
Study: NCT05109195

Intervention type: OTHER
Intervention: Standard of Care (SOC)
Description: Participants will not receive any intervention as a part of this study. Participants will receive SOC treatment.
Study: NCT05520450

Intervention type: BEHAVIORAL
Intervention: Telematic support group
Description: The participation of each patient in the study has been established for 4 months; the first and last months correspond to the evaluation phase, the remaining two months are for the intervention. A total of 7 group sessions of 90 minutes duration and weekly frequency are scheduled, carried out via telematics and conducted by an emotional well-being professional, a nurse and a social worker. In this context, it is guaranteed that patients will receive the care, visits and treatments usually used for people who have presented their clinical situation. The only difference between participating in the intervention and not participating in the intervention is the participation in a telematic support group and some additional assessments, i.e. not routinely carried out, which are part of this project. The intervention will be carried out in a group format, with a maximum of 12 patients per session.
Study: NCT05406570

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standardized ventilation
Description: Patient will be ventilated with tidal volume 6 mL/kg predicted body weight (PBW) and positive end-expiratory pressure (PEEP) according to the PEEP-FiO2 table of the ARMA trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standardized ventilation
Description: Patient will be ventilated with tidal volume 6 mL/kg predicted body weight (PBW) and positive end-expiratory pressure (PEEP) according to the PEEP-FiO2 table of the ARMA trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized ventilation
Description: Patient will be ventilated with PEEP according to the PEEP-FiO2 table of the ARMA trial. Tidal volume will be selected as the tidal volume minimizing cardiopulmonary interactions as assessed on arterial pressure tracing, during a VT trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Personalized ventilation
Description: Patient will be ventilated with PEEP according to the PEEP-FiO2 table of the ARMA trial. Tidal volume will be selected as the tidal volume minimizing cardiopulmonary interactions as assessed on arterial pressure tracing, during a VT trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group.
Study: NCT05847543

Intervention type: OTHER
Intervention: Stool diaper data and sample collection
Description: Stool diaper data and sample collection

Intervention type: OTHER
Intervention: Stool diaper data and sample collection
Description: Stool diaper data and sample collection

Intervention type: OTHER
Intervention: Stool diaper data and sample collection
Description: Stool diaper data and sample collection
Study: NCT05424315

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: 10mg Tab once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucose Tab
Description: Placebo Oral Tablet
Study: NCT06267508

Intervention type: PROCEDURE
Intervention: Maternal HIV viral load testing at delivery for VHT risk assessment
Description: Maternal HIV viral load testing will be performed for all mothers enrolled in the study at delivery. Results will be used along with WHO-defined clinical criteria to determine risk status for VHT. The intervention also includes personnel to support the additional testing volume and management of high-risk cases and eHealth solutions for communication of test results between health facilities.
Study: NCT04745806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiGraft
Description: Whole blood clot (WBC) gel
Study: NCT05026619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information about age-related fertility
Description: The following information is provided:~Age and fertility IVF success rates and side effects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information about policy initiatives
Description: The following information is provided:~Assisted reproductive technology treatment subsidies Other fertility-related policies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Information about diabetes
Description: The following information is provided:~Diabetes risk factors and treatment Diabetes-related policies
Study: NCT04504136

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serial Biopsy
Description: During the initial colonoscopy, 16-20 biopsies will be collected in addition to standard of care biopsies, and biopsy sites will be tattoed. Patients will return for a follow-up colonoscopy 4-35 days later. An additional 16-20 biopsies will be collected in a biopsy of the biopsy approach.
Study: NCT06483828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dental Anxiety Coping Module
Description: Dental tour where participants will be introduced to the dental clinic setting while Expressive Art Therapy, participants will engage with activity of making collage and finger painting.
Study: NCT04718896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimekizumab
Description: Study participants will receive subcutaneously administered bimekizumab (BKZ) at pre-specified time points during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimekizumab
Description: Study participants will receive subcutaneously administered bimekizumab (BKZ) at pre-specified time points during the study.
Study: NCT06114485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VIPA Treatment Program
Description: Participants will receive and Alexa device with a behavioral activation program, along with a detailed guidebook about how to utilize the Alexa device and the VIPA program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alexa with Guidebook
Description: Participants will receive an Alexa device with a detailed guidebook on how to use the device.
Study: NCT05051735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Paracetamol 500 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04504136

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serial Biopsy
Description: During the initial colonoscopy, 16-20 biopsies will be collected in addition to standard of care biopsies, and biopsy sites will be tattoed. Patients will return for a follow-up colonoscopy 4-35 days later. An additional 16-20 biopsies will be collected in a biopsy of the biopsy approach.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serial Biopsy
Description: During the initial colonoscopy, 16-20 biopsies will be collected in addition to standard of care biopsies, and biopsy sites will be tattoed. Patients will return for a follow-up colonoscopy 4-35 days later. An additional 16-20 biopsies will be collected in a biopsy of the biopsy approach.
Study: NCT04990544

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 202-CoV low adjuvant dose
Description: standard dose of 202-CoV with low dose CpG / alum adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 202-CoV low adjuvant dose
Description: standard dose of 202-CoV with low dose CpG / alum adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 202-CoV low antigen dose
Description: low dose of 202-CoV with CpG / alum adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 202-CoV low antigen dose
Description: low dose of 202-CoV with CpG / alum adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 202-CoV standard dose
Description: standard dose 202-CoV with CpG / alum adjuvant
Study: NCT05865535

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-380
Description: AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Study: NCT04990544

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 202-CoV standard dose
Description: standard dose 202-CoV with CpG / alum adjuvant

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution
Study: NCT05846477

Intervention type: DEVICE
Intervention: MySpine
Description: patient specific guide for screw positioning

Intervention type: DEVICE
Intervention: MySpine
Description: patient specific guide for screw positioning
Study: NCT06191133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate is an FDA approved drug for cardiovascular indications and have decades of data supporting a favorable safety profile event with chronic use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate is an FDA approved drug for cardiovascular indications and have decades of data supporting a favorable safety profile event with chronic use.
Study: NCT05603351

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Men with a positive MR test are planned for a targeted MRI/US fusion and systematic prostate biopsy.~Men with a positive blood marker (either PSA, PSAD, or PHI) are planned for a systematic 12 core biopsy. Positive test results are PSA ≥ 3, integrated marker PSAD ≥ 0.15, and PHI ≥ 35.
Study: NCT06628141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional support tool
Description: Nutritional support tool
Study: NCT06627790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mouthwash preparation
Description: Participants will be divided into two groups Group A and Group B Both the groups will receive thorough scaling and root planing at required sites. Use of mouthwash preparation is adviced for 8 weeks and discontinue after for 4 weeks. The Visual analogue scale Hypersensitivity will be assessed via Visual Analogue Scale at 4, 8 and 12 week interval

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwash preparation
Description: Participants will be divided into two groups Group A and Group B Both the groups will receive thorough scaling and root planing at required sites. Use of mouthwash preparation is adviced for 8 weeks and discontinue after for 4 weeks. The Visual analogue scale Hypersensitivity will be assessed via Visual Analogue Scale at 4, 8 and 12 week interval
Study: NCT06223724

Intervention type: DEVICE
Intervention: STOP
Description: Software to measure impedance telemetry data